Galectin Therapeutics Inc.

Galectin Therapeutics is a clinical-stage biotech built entirely around belapectin (GR-MD-02), a galectin-3 inhibitor in Phase 3 for MASH cirrhosis with portal hypertension. The equity trades as a call option on the Phase 3 outcome, and the balance sheet was just materially recapitalized.

• The Aug 4 conversion of $105.8M of debt into 34.4 million equity shares by longtime backer Richard Uihlein (who now owns 49.3% of the company per the SC 13D/A) removes near-term insolvency risk and re-lines the balance sheet — but it also confirms the equity dilution that had already been happening in the tape.
• The June 24 FDA Type C meeting produced positive alignment on the belapectin Phase 3 path in MASH cirrhosis and portal hypertension — that's a real de-risking event for the regulatory pathway, and the stock initially popped 11% on it before drifting back.
• Q1 EPS was -$0.077 on essentially $0 revenue with -$3.9M FCF — the operating cash burn is manageable now that the debt overhang is fixed, but the equity value is 100% tied to whether belapectin's Phase 3 hits the primary endpoint on time.
• Analyst FY26 revenue at $180M is aspirational (there's no near-term revenue anywhere); the actual read is that if belapectin approves, the addressable MASH-cirrhosis market is enormous, and the current $227M market cap is modest relative to any successful outcome.

Tonight's Aug 13 earnings likely doesn't move the stock materially — the print is a formality for a pre-revenue biotech. The real event is the Phase 3 topline readout (indicated for 2026-2027 timing), where a positive result triggers a 2-4x move and a failure triggers a 60-80% one-day drop — this is the classic biotech binary.